Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (the CADILLAC trial)

Dale T. Ashby, Eve A. Aymong, James E. Tcheng, Cindy L. Grines, David A. Cox, Roxana Mehran, Eulogio Garcia, John J. Griffin, Giulio Guagliumi, Thomas Stuckey, Mark Turco, Alexandra J. Lansky, Gregg W. Stone

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The utility of glycoprotein IIb/IIIa receptor inhibitors as a "bail-out" modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%) crossed over and received abciximab for procedural complications or suboptimal angioplasty results. Compared with patients who received routine upfront abciximab, those treated with bail-out abciximab had markedly lower rates of Thrombolysis In Myocardial Infarction grade 3 flow and increased rates of hemorrhagic and ischemic complications at 30 days and 1 year.

Original languageEnglish
Pages (from-to)1091-1094
Number of pages4
JournalAmerican Journal of Cardiology
Volume92
Issue number9
DOIs
StatePublished - 1 Nov 2003

Fingerprint

Dive into the research topics of 'Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (the CADILLAC trial)'. Together they form a unique fingerprint.

Cite this